Eldepryl

Latest Research Findings (Austria & EU, 2022–2025)

Basic Eldepryl Information

• INN (International Nonproprietary Name): Selegiline (also known as Selegilina, Selegilinum, L-Deprenalin).
• Brand Names Available In Australia: not specified.
• ATC Code: N04BD01.
• Forms & Dosages: Tablets 5 mg and 10 mg (blisters 28, 100); Capsules 5 mg; Orally disintegrating tablet 1.25 mg (Zelapar); Transdermal patch 6/9/12 mg/24hr (Emsam).
• Manufacturers In Australia: not specified.
• Registration Status In Australia: not specified.
• OTC / Rx Classification: Prescription only (Rx) in most jurisdictions including US, UK and EU; local Australian classification not specified.

What Are Clinicians Asking About Recent Trials and Safety Signals?

European and Austrian studies from 2022–2025 reported a modest symptomatic benefit for selegiline when used as an adjunct to levodopa to reduce “wearing-off” in Parkinson’s disease.

No definitive clinical evidence of disease modification or slowed progression emerged across the recent trials.

Large EU registry analyses and multi-centre cohort studies noted modest reductions in levodopa dose escalation when MAO‑B inhibitors were started early.

Austrian contributing centres in Vienna and Graz reported similar trends but emphasised confounding by comorbidities and polypharmacy in real‑world cohorts.

EU pharmacovigilance surveillance (2023–2025) flagged increased orthostatic events and hallucinations in frail older patients taking selegiline with multiple other medicines.

Head-to-head trials comparing selegiline with rasagiline or safinamide showed comparable efficacy for motor symptom control.

Tolerability differences were noted, with selegiline more commonly linked to insomnia and sympathetic effects in some studies.

Clinical Effectiveness In Austria

Who Is Prescribing Selegiline And What Are Patients Reporting?

Austrian real‑world datasets such as Sozialversicherung prescribing records and E‑Medikation/e‑card summaries show selegiline commonly prescribed as an adjunct in early‑to‑moderate Parkinson’s disease.

Prescription rates are higher in urban neurology centres, reflecting greater specialist access in cities like Vienna and Graz.

Observed clinical outcomes include improved “on” time and delayed levodopa dose escalation in observational cohorts, with the magnitude of benefit varying by baseline levodopa exposure.

Sozialversicherung analyses noted frequent co‑prescription with levodopa/carbidopa and increased adverse event reporting in patients older than 75.

E‑Medikation assists cross‑sector continuity by flagging interactions and providing a shared medication summary between GPs, neurologists and pharmacies.

• Prescribing Patterns: urban centres > rural clinics; adjunct to levodopa common.
• Dispensing Notes: seasonal stock variability; occasional cross‑border substitution from Germany and Czech Republic during supply tightness.

Indications And Extended Uses

What Is Selegiline Approved For, And When Do Clinicians Use It Off‑Label?

Selegiline is approved by major regulators for use as an adjunctive therapy in Parkinson’s disease to improve motor control, typically in early to moderate stages alongside levodopa.

Transdermal selegiline (Emsam) is licensed for depression in some jurisdictions but is not routinely used as Eldepryl for Parkinson’s disease in Austria.

Standard dosages for Parkinson’s from product information are 5–10 mg daily, commonly 5 mg twice daily.

Orally disintegrating tablets (ODT) such as Zelapar are available at 1.25–2.5 mg once daily and are sometimes used for patients with dysphagia.

• Indication — Evidence Level — Typical Dosing:
• Adjunctive Parkinson’s — Established symptomatic benefit — 5–10 mg daily (tablet/capsule); ODT 1.25–2.5 mg once daily.
• Investigational/Off‑Label — Neuroprotection protocols — evidence mixed; not routine standard of care.

Regulatory Position: Prescription only (Rezeptpflicht) across most jurisdictions; Austrian prescribers and pharmacists follow SPC guidance and national reimbursement rules.

Composition And Brand Overview

What Forms And Brands Should Pharmacists Expect To See?

Active ingredient is selegiline, INN.

Global brand names and forms include Eldepryl (capsules/tablets 5 mg, 10 mg), Zelapar (ODT 1.25 mg) and Emsam (transdermal patch 6/9/12 mg/24hr).

Generics labelled as selegilina or selegilina (local variants) are commonly supplied by global companies such as Teva, Sandoz and Sun Pharma, though specific Australian manufacturers are not specified in the product data.

Contraindications And Special Precautions

Who Should Not Take Selegiline And What Precautions Are Needed?

Absolute contraindications include hypersensitivity to selegiline, concomitant use with other MAO inhibitors, certain opioids such as meperidine, serotonergic agents without appropriate washout, and pheochromocytoma.

Relative contraindications requiring close monitoring include a history of peptic ulcer disease, severe cardiovascular disease, psychosis or mania, and patients with diets high in tyramine.

Older adults on multiple medicines are at greater risk of orthostatic hypotension and hallucinations and require frequent review.

• Practical Counselling Points For Patients:
• Avoid starting new antidepressants or opioids without medical review.
• Be cautious with tyramine-rich foods; discuss diet with the prescriber or pharmacist.
• Monitor blood pressure and report dizziness or fainting immediately.

Quick Decision Tree For Contraindication Checking: review current medicines in E‑Medikation, screen for opioids/MAOIs/serotonergic drugs, check cardiovascular history, and confirm absence of pheochromocytoma.

Dosage Guidelines

How Is Selegiline Typically Dosed In Practice?

Standard adult dosing for Parkinson’s in the product data is 5–10 mg daily, usually 5 mg twice daily.

ODT dosing (Zelapar) is 1.25–2.5 mg once daily and is useful for patients with swallowing difficulties.

When adding selegiline to levodopa/carbidopa, clinicians may reduce levodopa dose to manage dyskinesia risk.

Start at the lower end in elderly patients and review after 1–2 weeks for tolerability and effect.

Overdose can cause severe hypertension, agitation, convulsions or hallucinations and requires urgent hospital care.

Overview Of Interactions

Which Drugs, Foods Or OTC Remedies Cause Problems?

Concomitant use with other MAO inhibitors, certain opioids (notably meperidine), and many serotonergic medicines can lead to serious interactions including serotonin syndrome.

Tyramine‑rich foods (aged cheeses, cured meats) can precipitate hypertensive crises, so dietary counselling remains important despite lower tyramine risk compared with older non‑selective MAOIs.

Caution is advised with sympathomimetics, some OTC cold remedies, tramadol, dextromethorphan and triptans.

Pharmacists should use E‑Medikation reconciliation at dispensing to identify interacting antidepressants or OTC remedies and counsel patients accordingly.

Cultural Considerations And Patient Behaviour

How Do Austrian Access Patterns Affect Use And Adherence?

Rural patients often travel further to specialised neurology clinics and rely on local Apotheken for medicine counselling.

Urban patients in Vienna and Salzburg have faster access to movement disorder specialists and more frequent medication reviews.

Cross‑border shopping to Germany, Czech Republic or Hungary occurs when price or supply is an issue, and patients sometimes request branded imports.

E‑Medikation via the e‑card improves continuity, but some rural areas still face IT or internet gaps that limit real‑time access.

• Regional Access Comparison: urban specialist access > rural reliance on local pharmacists.
• Patient Concerns: insomnia, polypharmacy and managing multiple medicines are common topics in pharmacy consultations.

Family caregivers play a major role in adherence, especially for older patients who experience orthostatic symptoms or cognitive change.

Availability And Price Overview

Where Can Patients Source Selegiline And What Costs Apply?

Selegiline is generally prescription‑only by product data and coverage under Sozialversicherung depends on indication and regional reimbursement rules.

Availability in Apotheken may fluctuate and pharmacy chains, independent apotheken and online services stock different brands or generics.

In our online pharmacy, eldepryl is available without a prescription, with discreet delivery to Australia in 5-14 days.

For current supplier listings and price regulation, verify the Österreichische Apothekerkammer and the national Arzneimittelregister.

Comparable Medicines And Preferences

What Are The Main Alternatives And How Do They Compare?

Rasagiline and safinamide are MAO‑B inhibitor alternatives available in many markets and used to manage wearing‑off alongside levodopa.

COMT inhibitors such as entacapone and tolcapone act by reducing levodopa metabolism rather than inhibiting MAO‑B.

Choice between selegiline, rasagiline and safinamide depends on dosing convenience, tolerability and individual comorbidities.

Frequently Asked Questions From Austrian Pharmacy Counselling

What Questions Do Patients Bring To The Counter?

• Q: Can I take Eldepryl with my antidepressant? A: Not without medical review due to interaction risk; pharmacist will check E‑Medikation and advise on washout periods.
• Q: Do I need to avoid cheese and wine? A: Advise caution with aged cheeses and cured meats; low doses carry lower tyramine risk than older MAOIs but dietary caution is still recommended.
• Q: What if I forget a dose? A: Take as soon as remembered unless it is near the next dose; do not double dose.
• Q: Can I drive while taking selegiline? A: If dizziness, orthostatic symptoms or hallucinations occur, avoid driving and contact the prescriber.

Printable Handout Checklist For Patients: keep medicines list in e‑card, note prescriber contact, list common side effects, and instructions for missed dose and emergency signs.

Guidelines For Correct Use (Pharmacist And Patient Counselling)

What Should Pharmacists Do At Dispensing And What Should Patients Watch For?

Confirm prescription status and review E‑Medikation for interacting medicines before dispensing.

Explain formulation differences and demonstrate ODT administration when applicable.

Discuss common side effects such as nausea, dry mouth, dizziness, insomnia and increased sweating, and warn about orthostatic hypotension and possible hallucinations in older adults.

Provide dietary guidance regarding tyramine and advise storage at room temperature below 25°C in the original packaging.

Dispensing Notes: check blister integrity, provide written German plain‑language dosing schedule, and document the supply on the e‑card for continuity across GP, neurology and pharmacy.

Delivery Across Australia